Prognostic significance of MET amplification and expression in gastric cancer: A systematic review with meta-analysis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Peng, Zhi ^a   Zhu, Yan ^a   Wang, Qianqian ^b   Gao, Jing ^a   Li, Yilin ^a   Li, Yanyan ^a   Ge, Sai ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Beijing Jishuitan Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; MET GENE; OVERALL SURVIVAL; STOMACH CANCER; SYSTEMATIC REVIEW;

GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84897124916     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084502     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, et al. (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125: 666-673.
3. Asaoka Y, Ikenoue T, Koike K (2011) New targeted therapies for gastric cancer. Expert Opin Investig Drugs 20: 595-604.
4. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG (2008) Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44: 946-953.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
6. Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834-848.
7. Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9: 314-326.
8. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
9. Jatoi I, Benson JR, Liau SS, Chen Y, Cisco RM, et al. (2010) The role of surgery in cancer prevention. Current Problems in Surgery 47: 750-830.
10. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
11. de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, et al. (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 101: 149-159.
12. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105: 93-103.
13. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, et al. (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88: 1456-1466. (Pubitemid 26340047)
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072.
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
17. Egger M, Smith GD (1998) Bias in location and selection of studies. BMJ 316: 61-66.
18. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, et al. (1998) Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55: 475-481. (Pubitemid 28396062)
19. Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, et al. (2012) Coexpression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 130: 2912-2921.
20. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, et al. (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29: 4789-4795.
21. Li Y, Chen CQ, He YL, Cai SR, Yang DJ, et al. (2012) Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol 106: 304-310.
22. Shi J, Yao D, Liu W, Wang N, Lv H, et al. (2012) Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 13: 4714-4726.
23. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, et al. (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25: 1517-1524.
24. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, et al. (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107: 325-333.
25. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS (2001) Overexpression of the cmet protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol 40: 638-643.
26. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, et al. (2008) The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19: 1477-1483.
27. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, et al. (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902. (Pubitemid 29202761)
28. Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, et al. (1998) The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82: 2112-2122. (Pubitemid 28240817)
29. Zhao J, Zhang X, Xin Y (2011) Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol 26: 1111-1120.
30. Kubicka S, Claas C, Staab S, Kuhnel F, Zender L, et al. (2002) p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci 47: 114-121. (Pubitemid 34075026)
31. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, et al. (2011) RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 12: 9-46.
32. Zhuang X, Zheng J, Lin S, Sun G, Li Y (2000) [The prognostic significance of expression of c-met oncogene and its relation to gastric mucosal lesions]. Zhonghua Bing Li Xue Za Zhi 29: 409-411.
33. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, et al. (2002) The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20: 975-981. (Pubitemid 35175137)
34. Sierra JR, Tsao MS (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3: S21-35.
35. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P (2011) Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104: 1440-1451.
36. Yonemura Y, Kaji M, Hirono Y, Fushida S, Tsugawa K, et al. (1996) Correlation between overexpression of c-met gene and the progression of gastric cancer. Int J Oncol 8: 555-560. (Pubitemid 26082173)
37. Yonemura Y, Nojima N, Kaji M, Kawamura T, Fushida S, et al. (1997) E-cadherin and c-met expression as a prognostic factor in gastric cancer. Oncology Reports 4: 743-748. (Pubitemid 27286982)
38. Amemiya H, Menolascino F, Pena A (2010) [Role of the expression of c-Met receptor in the progression of gastric cancer]. Invest Clin 51: 369-380.
39. Wu HB, Zhang P, Li XQ, Wu JG, Yu JW, et al. (2009) Expression of c-met, e2f-1 and Ki-67 in tissues of gastric cancer. Journal of Shanghai Jiaotong University (Medical Science) 29: 1482-1486.
40. Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, et al. (2010) A randomized phase iii study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology 65: 1009-1021.
41. Ge SH, Wu XJ, Wang XH, Xing XF, Zhang LH, et al. (2011) Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients. Chinese Journal of Cancer Research 23: 153-159.
42. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, et al. (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227-232. (Pubitemid 23030031)
43. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, et al. (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29: 4803-4810.
44. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, et al. (2011) MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20: 1021-1027.